UPDATE : Monday, September 7, 2020
상단여백
HOME Policy
Clinical trials on 3 Covid-19 vaccine candidates to start this year
  • By Kim Eun-young
  • Published 2020.08.14 17:52
  • Updated 2020.08.16 12:14
  • comments 0

The Ministry of Health and Welfare said clinical trials on the three candidate materials for the Covid-19 vaccine are likely to begin within this year.

At a daily Covid-19 briefing on Thursday, Kwon Jun-wook, deputy director of the Korea Centers for Disease Control and Prevention, said the ministry is providing extensive support for developing three vaccine candidates from the second half of this year for completion by next year.

Kwon Jun-wook, deputy director of the Korea Centers for Disease Control and Prevention, said the government expects the clinical trials on three locally developed candidate materials for the Covid-19 vaccine to start within this year. (KCDC)

The three vaccine candidates likely to enter clinical trials within this year are a synthetic antigen vaccine and two others using deoxyribonucleic acid (DNA). According to the KCDC, SK Bioscience is developing the synthetic antigen vaccine, and Genexine and GeneOne Life Science are working on DNA vaccines.

Genexine has won approval for phase 1, 2a clinical trials on June 11, and SK Bioscience and GeneOne Life Science are conducting an animal study to check for toxicity.

“There are four platforms for vaccines, and three companies are leading research on two platforms in Korea,” Kwon said. “We expect the clinical trials on all three candidates to start within this year.”

KCDC also said that it had administered Remdesivir, imported as a treatment for Covid-19, on all 119 patients at 35 hospitals who had requested to do so.

key@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Kim Eun-young
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top